Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Friday. The firm set a “sell” rating on the stock.

Bio-Path Trading Up 4.8 %

BPTH opened at $0.91 on Friday. The firm’s fifty day moving average price is $1.00 and its two-hundred day moving average price is $1.67. Bio-Path has a fifty-two week low of $0.80 and a fifty-two week high of $12.43.

Bio-Path (NASDAQ:BPTH) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same period in the prior year, the firm earned ($10.60) EPS. On average, sell-side analysts anticipate that Bio-Path will post -6.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent filing with the Securities & Exchange Commission. 5.74% of the stock is currently owned by institutional investors and hedge funds.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.